Risk of Cancer-Specific Death May Remain Elevated for 30 Years
Patients with certain cancers have an increased risk of cancer-specific mortality that persists for 30 to 35 years after diagnosis.
Urologic Cancers
UROLOGIC CANCER ADVISOR
FEATURED CONTENT
-
-
Eponyms in Oncology: Lynch Syndrome
This weekly series highlights eponyms in oncology. This week, we explore the history and namesake of Lynch syndrome. -
Eponyms in Oncology: Virchow’s Node
This weekly series highlights eponyms in oncology. This week, we explore the history and namesake of Virchow’s node. -
Many Immune Checkpoint Inhibitor Combination Therapies Show No Evidence of Drug Synergy
The efficacy of many combination therapies may be due to independent drug action, not synergistic or additive effects. -
Prostate Cancer ADT Has Fewer Cardiovascular Risks Than Expected
Investigators found that men receiving androgen deprivation therapy for prostate cancer had a 1% rate of major adverse cardiovascular events.
UROLOGIC CANCERS NEWS
HRQOL Data Support First-Line Lenvatinib-Pembrolizumab in Advanced Renal Cell Carcinoma
New Model Improves Life Expectancy Estimates in Prostate Cancer Population
Risk of Neurologic AEs Lower With Immune Checkpoint Inhibitors Than With Other Cancer Therapies
Orteronel Does Not Improve Overall Survival in Prostate Cancer
NAFLD Associated With Long-Term Risk for Extrahepatic Cancers
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Urologic Cancers
Loading... 
Loading...